AVBP FY 2024 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$94M

Net Income

-$80M

EPS (Diluted)

$-2.56

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$70M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$275M

Total Liabilities

$17M

Stockholders' Equity

$258M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$94M	-$75M	-26.4%
Net Income	-$80M	-$69M	-16.1%